Vitrolife AB
STO:VITR
Vitrolife AB
Revenue
Vitrolife AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vitrolife AB
STO:VITR
|
Revenue
kr3.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
|
Biogaia AB
STO:BIOG B
|
Revenue
kr1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Revenue
kr997.9m
|
CAGR 3-Years
62%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Probi AB
STO:PROB
|
Revenue
kr630.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
18%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Revenue
kr26B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
26%
|
|
|
BioArctic AB
STO:BIOA B
|
Revenue
kr257.4m
|
CAGR 3-Years
123%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Vitrolife AB
Glance View
Vitrolife AB is a Swedish company that has carved out a significant niche within the biotechnology sector, particularly within reproductive health. Founded in 1994, Vitrolife focuses on the development, production, and commercialization of products designed to optimize fertility treatments. The company’s offerings include a wide range of medical devices and culture media critical for in vitro fertilization (IVF) procedures. These products are used by fertility clinics across the globe, enhancing every stage of assisted reproduction — from egg retrieval and sperm preparation to embryo transfer. This comprehensive approach not only amplifies treatment outcomes but also strengthens Vitrolife's position as a pivotal player in a market where scientific advancement and patient care converge. The company’s business model thrives on a robust combination of research-driven innovation and strategic acquisitions. By continuously refining its product lines and leveraging strategic partnerships with clinics and research institutes, Vitrolife ensures that it remains at the cutting edge of the rapidly evolving fertility landscape. Revenue streams flow in through the sales of these critical fertility products, supported by a well-established distribution network that bridges its Swedish roots with a global customer base. With a commitment to quality and efficacy, Vitrolife makes money by delivering solutions that enhance the success rates of fertility treatments, making the dream of parenthood possible for many around the world.
See Also
What is Vitrolife AB's Revenue?
Revenue
3.6B
SEK
Based on the financial report for Mar 31, 2025, Vitrolife AB's Revenue amounts to 3.6B SEK.
What is Vitrolife AB's Revenue growth rate?
Revenue CAGR 10Y
21%
Over the last year, the Revenue growth was 3%. The average annual Revenue growth rates for Vitrolife AB have been 21% over the past three years , 19% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet